Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Dermatology

Understanding Porphyria Cutanea Tarda (PCT)

At a Glance

Porphyria cutanea tarda (PCT) is a treatable metabolic liver disorder that causes severe skin sensitivity, blistering, and dark urine. It occurs when a UROD enzyme deficiency leads to a buildup of porphyrins, often unmasked by triggers like iron overload, alcohol use, or Hepatitis C.

Porphyria cutanea tarda (PCT) is the most common form of porphyria worldwide [1][2]. While it is technically classified as a rare disease, it is frequently encountered by specialists who treat skin and liver conditions. For many, a diagnosis of PCT feels like a mystery, but it is a well-understood and highly treatable medical condition.

At its core, PCT is a liver-based metabolic disorder that primarily shows up on your skin. It occurs when your body cannot properly process porphyrins—natural compounds used to make heme, which carries oxygen in your blood [3][4]. When these porphyrins build up, they travel to the skin, where they react to light and cause the symptoms you may be experiencing. You might also notice your urine appearing unexpectedly dark, tea-colored, or red/pink, which is a classic sign of excess porphyrins leaving the body [5].

The Role of the UROD Enzyme

To understand PCT, it helps to think of your body’s heme production as an assembly line. UROD (uroporphyrinogen decarboxylase) is a critical enzyme that acts like a worker on that line, clearing away intermediate compounds so the process can finish [3].

In people with PCT, this “worker” is either missing or not working efficiently [4].

  • The Accumulation: Because the UROD enzyme isn’t clearing the porphyrins, they “overflow” from the liver into the bloodstream and eventually settle in the skin and urine [6].
  • The Light Reaction: These stored porphyrins are highly sensitive to light. When sunlight (specifically visible light) hits the skin, it “activates” the porphyrins, leading to the characteristic blisters, fragile skin, and scarring [1][7].

Stabilization: Three Key Facts

When you are first diagnosed, it is normal to feel overwhelmed. These three facts can help ground your perspective:

  1. It is Highly Treatable: PCT is often considered the most “curable” form of porphyria. With standard care, most patients achieve full clinical remission, where skin symptoms disappear entirely [8][9].
  2. It is Not an ‘Acute’ Porphyria: Unlike some other types of porphyria, PCT does not cause sudden, life-threatening “attacks” of abdominal pain or neurological issues [10].
  3. It Often Requires an ‘Unmasking’ Factor: Most people with the UROD deficiency only develop symptoms when a secondary trigger “unmasks” the condition. These triggers can include iron overload, alcohol use, smoking, or certain viral infections like Hepatitis C [4][5][11].

What PCT Is and Isn’t

Understanding the boundaries of this condition can help reduce anxiety:

  • It IS a metabolic condition: It is a physical disruption in how your liver handles specific chemicals.
  • It IS a sun-sensitive condition: You will need to protect your skin from visible light (not just UV rays) until your porphyrin levels normalize [1].
  • It IS NOT contagious: You cannot give PCT to anyone else.
  • It IS NOT a skin-only disease: While the symptoms are on the skin, the cause is in the liver, which is why your doctor will likely check your liver health [7].

Navigating the Emotional Impact

Receiving a diagnosis that changes how you interact with the world—such as needing to avoid the sun—can be emotionally taxing. Many patients report feelings of:

  • Social Isolation: The need to avoid outdoor activities or the appearance of skin lesions can lead to withdrawing from social circles [12].
  • Anxiety: It is common to feel “on edge” about sun exposure or the appearance of new blisters [12].
  • Frustration: Finding the right balance of lifestyle changes and medical treatment takes time.

Validation of these feelings is a key part of your recovery. You are not just treating a set of lab values; you are adjusting to a new way of protecting your health. As your treatment progresses and your porphyrin levels drop, the skin sensitivity typically resolves, allowing you to return to your normal lifestyle.

Common questions in this guide

What causes Porphyria Cutanea Tarda (PCT)?
PCT is caused by an issue in your liver, specifically a deficiency in the UROD enzyme. This prevents your body from properly processing porphyrins, causing them to build up in your bloodstream and eventually settle into your skin and urine.
Why does PCT cause skin blisters?
When excess porphyrins build up in your skin, they become highly sensitive to visible light. When sunlight hits your skin, it activates these porphyrins, leading to the characteristic blistering, skin fragility, and scarring.
Is Porphyria Cutanea Tarda curable?
Yes, PCT is considered the most curable form of porphyria. With standard medical care and trigger management, most patients achieve a full clinical remission where their skin symptoms disappear entirely.
What triggers a PCT flare-up?
While a UROD enzyme deficiency is the root cause, symptoms are often unmasked by secondary triggers. Common triggers include excess iron levels, heavy alcohol consumption, smoking, and certain viral infections like Hepatitis C.
Why is my urine dark or tea-colored?
Unexpectedly dark, tea-colored, or red/pink urine is a classic sign of PCT. It occurs because your body is trying to eliminate the high levels of excess porphyrins through your urine.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How will we monitor my UROD enzyme activity or porphyrin levels to track my progress?
  2. 2.What tests will be done to check for underlying triggers like iron levels (ferritin) or Hepatitis C?
  3. 3.Are there specific medications or supplements I should avoid that might worsen PCT?
  4. 4.How often do I need follow-up appointments once my skin begins to clear?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Porphyria: awareness is the key to diagnosis!

    Heymans B, Meersseman W

    Acta clinica Belgica 2022; (77(3)):703-709 doi:10.1080/17843286.2021.1918876.

    PMID: 33938396
  2. 2

    Dermatologic Manifestations of Chronic Hepatitis C Infection.

    Sayiner M, Golabi P, Farhat F, Younossi ZM

    Clinics in liver disease 2017; (21(3)):555-564 doi:10.1016/j.cld.2017.03.010.

    PMID: 28689593
  3. 3

    A Case Report of Porphyria Cutanea Tarda with Hepatitis-C Virus Co-infection.

    Hasan MN, Bhuiyan MR, Ferdous SH, et al.

    Mymensingh medical journal : MMJ 2023; (32(2)):584-586.

    PMID: 37002774
  4. 4

    Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct-acting anti-virals.

    Sastre L, To-Figueras J, Lens S, et al.

    Alimentary pharmacology & therapeutics 2020; (51(10)):968-973 doi:10.1111/apt.15703.

    PMID: 32294804
  5. 5

    [Porphyria cutanea tarda].

    Mistegård J, Christiansen AL, Vestergaard C, et al.

    Ugeskrift for laeger 2025; (187(38)) doi:10.61409/V11240832.

    PMID: 41025764
  6. 6

    Blistering Disease During the Treatment of Chronic Hepatitis C With Ledipasvir/Sofosbuvir.

    Cash J, Skinner A, Cash S, et al.

    Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2019; (36(Suppl 2)):S11-S13.

    PMID: 30983856
  7. 7

    Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs.

    Balogun O, Nejak-Bowen K

    Seminars in liver disease 2024; (44(2)):209-225 doi:10.1055/s-0044-1787076.

    PMID: 38772406
  8. 8

    Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C.

    Bonkovsky HL, Rudnick SP, Ma CD, et al.

    Digestive diseases and sciences 2023; (68(6)):2738-2746 doi:10.1007/s10620-023-07859-8.

    PMID: 36811718
  9. 9

    A Rare Case of Hereditary Hemochromatosis Presenting With Porphyria Cutanea Tarda.

    Varada N, Tun KM, Chang MJ, et al.

    Cureus 2023; (15(7)):e41299 doi:10.7759/cureus.41299.

    PMID: 37539416
  10. 10

    [An overview of porphyrias].

    Lindemann H, Diehl-Wiesenecker E, Gerischer L, Frank J

    Dermatologie (Heidelberg, Germany) 2024; (75(7)):539-547 doi:10.1007/s00105-024-05370-3.

    PMID: 38902527
  11. 11

    Evolution of HCV associated porphyria cutanea tarda after HCV sustained virologic response by direct acting antivirals.

    García-Fraile LJ, García-Buey L, Alonso Cerezo C, et al.

    Gastroenterologia y hepatologia 2022; (45(4)):249-255 doi:10.1016/j.gastrohep.2021.09.001.

    PMID: 34562521
  12. 12

    Epidemiology of cutaneous porphyria in Israel: a nationwide cohort study.

    Edel Y, Mamet R, Snast I, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2020; (34(1)):184-187 doi:10.1111/jdv.15769.

    PMID: 31264284

This page provides an educational overview of Porphyria Cutanea Tarda (PCT). It is for informational purposes only and does not replace professional medical advice from your dermatologist or hepatologist.

Get notified when new evidence is published on Porphyria cutanea tarda.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.